Texila International Journal of Public Health
Special Issue 2-2025
DOI: 10.21522/TIJPH.2013.SE.25.02.Art003

Intersection of Precision Medicine and Cancer Therapy

G. Manivannan[1], S. Nimithap[2], R. Rathika[3] and A. Ganesh Kumar[4*]

[1]*Research Unit, Department of Psychiatry, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai – 602 105, Tamil Nadu, India*

[2]*Department of General Medicine, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai – 602 105, Tamil Nadu, India*

[3]*PG & Research Department of Biotechnology, Mahendra Arts & Science College (Autonomous), Namakkal-637 501, Tamil Nadu, India*

[4]*Department of Microbiology, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai – 602 105, Tamil Nadu, India*

Abstract

Customizing treatments according to each patient's distinct genetic, molecular, and clinical traits, precision medicine holds the potential to completely transform the way cancer is treated. Advances in immunotherapy, liquid biopsy technology, multi-omics, and gene editing methods like CRISPR are all contributing to this strategy. By combining these advancements, it will be possible to develop tailored medicines that focus on the underlying genetic causes of cancer, increasing the precision and efficacy of cancer treatments. Furthermore, machine learning and artificial intelligence provide strong instruments for forecasting therapy outcomes and refining therapeutic approaches. Widespread adoption is still hampered by issues like the intricacy of cancer genetics, the high expense of sophisticated therapies, restricted access in environments with limited resources, and the requirement for uniform clinical data. In order to alter global cancer treatment and improve patient outcomes, it will be imperative to address these issues and guarantee that all patients may benefit from precision medicine.

Keywords: *Cancer Treatment, CRISPR, Immunotherapy, Machine Learning, Precision Medicine.*

Introduction

Precision medicine, often known as customized medicine, is a cutting-edge approach to healthcare and treatment that considers individual differences in lifestyle, environment, and genes. Precision medicine, in contrast to the conventional one-size-fits-all approach to healthcare, customizes therapies to each patient's unique traits in an effort to maximize benefits and reduce negative effects. The use of genomic data is essential to precision medicine. Genetic testing enables medical professionals to find genetic mutations, polymorphisms, and other differences that may impact a patient's reaction to treatment thanks to developments in DNA sequencing technologies. For instance, patients with particular genetic markers respond better to some cancer treatments [1].

Pharmacogenomics is the study of how a person's genes affect how they react to medications. Precision medicine can help doctors prescribe the best medication at the optimum dose by identifying genetic characteristics that affect drug metabolism. This helps to reduce adverse drug reactions. Targeted therapies are medications or other materials that interfere with particular molecules involved in tumor growth in order to prevent the development and spread of cancer.

Received: 16.01.2025 ***Accepted: 12.02.2025*** ***Published on: 27.06.2025***

****Corresponding Author: drgkanbazhagan@gmail.com***

Targeted therapies seek to destroy malignant cells with little effect on healthy cells, in contrast to standard chemotherapy, which affects all fast-dividing cells [2].

Precision medicine looks at lifestyle and aspects in addition to genetic data. By combining these components, a more comprehensive understanding of health is offered, which improves preventative and treatment methods. Precision medicine has advanced significantly in several areas, especially uncommon genetic illnesses, cardiology, and oncology. For example, cardiovascular care employs genetic risk factors to predict susceptibility to heart disease, and cancer treatment increasingly includes genomic sequencing to select the best course of therapy [3].

Precision medicine has several obstacles to overcome despite its promise, such as the high expense of genomic testing, worries about data privacy, and the requirement for extensive clinical trials to confirm its efficacy [4]. However, it is projected that precision medicine will become more generally available as costs fall down and technology advances, transforming healthcare by providing more specialized and efficient treatments. The future of healthcare is represented by precision medicine, which promises to provide more individualized, efficient, and effective treatment alternatives. Customized therapies that enhance patient outcomes are made possible by the integration of lifestyle, environmental, and genetic data. Precision medicine has the potential to transform modern medicine as research advances and clinical applications grow [5].

Uncontrolled cell development and the ability to spread to other parts of the body are hallmarks of the complex group of diseases known as cancer. Genetic changes, such as mutations, amplifications, deletions, and translocations in the DNA of malignant cells, are what cause cancer at the molecular level. Malignancy may result from these genetic alterations' impact on several cellular processes that control DNA repair, apoptosis, and cell cycle progression. Oncogenes and tumor suppressor genes are two important gene groups that are frequently impacted by genetic changes linked to cancer. While tumor suppressor genes typically work to limit cell development and trigger apoptosis, oncogenes, when mutated or overexpressed, promote cell proliferation and survival. On the other hand, abnormalities in the RAS or MYC genes might trigger mechanisms that result in uncontrollably high cell division [6].

A common feature of many malignancies is genomic instability, which is defined by a high frequency of mutations and chromosomal changes. Point mutations, insertions, deletions, and chromosomal rearrangements are among the genetic changes that may occur more frequently as a result of this instability. For instance, chronic myelogenous leukemia (CML) frequently has the Philadelphia chromosome, a translocation between chromosomes 9 and 22. The BCR-ABL fusion gene is created as a result of this translocation and encodes a constitutively active tyrosine kinase that promotes leukemia cell growth [7].

Apart from genetic mutations, epigenetic modifications—which change gene expression without altering the DNA sequence—can also have an impact on cancer. Two important mechanisms of epigenetic regulation are histone modification and DNA methylation. Hypermethylation of tumor suppressor genes' promoter regions is one example of aberrant DNA methylation that can silence these genes and aid in the development of cancer. The development of cancer is not caused by all genetic changes. Certain mutations, referred to as "driver mutations," give the cancer cells a growth advantage, which directly contributes to carcinogenesis. On the other hand, "passenger mutations" are unintentional and do not contribute to the development of cancer. Targeted medicines that precisely inhibit these altered proteins have been developed as a result

of the identification of driver mutations in particular malignancies, such as EGFR mutations in non-small cell lung cancer or BRAF mutations in melanoma [8].

Next-generation sequencing (NGS), one of the advancements in genetic sequencing technologies, has made it possible to identify genetic changes in cancers, which helps with diagnosis and treatment. A patient's cancer's unique genetic profile is increasingly being used to inform personalized treatment plans, such as immunotherapies and targeted medicines. For instance, trastuzumab and other targeted medicines that inhibit the HER2 receptor are beneficial for individuals with HER2-positive breast cancer [9]. The growth and spread of cancer are mostly caused by genetic changes. More individualized cancer treatments are now possible thanks to our growing understanding of the molecular mechanisms behind these changes. Precision medicine is providing fresh hope for more potent cancer treatments by focusing on certain genetic changes, such as mutations in tumor suppressor genes or oncogenes. It is anticipated that more investigation into the genetic makeup of cancer will reveal new therapeutic targets and enhance patient outcomes [10, 11].

Genetic Profiling in Cancer Therapy

The science of cancer genomics has been completely transformed by the potent technique known as next-generation sequencing (NGS). Comprehensive and high-throughput study of genetic mutations, structural variations, and epigenetic alterations in cancers is made possible by NGS. More accurate cancer diagnosis, treatment planning, and the creation of customized medicines are made possible by this cutting-edge sequencing approach. NGS provides information about possible treatment targets and assists in identifying important genetic changes that propel the development of cancer by sequencing the DNA and RNA of tumors [12, 13].

By identifying alterations in several genes at once, NGS enables thorough analysis of a tumor's genetic composition. This method offers a more thorough and comprehensive picture of the tumor by detecting both known and unknown genomic changes. To select the best targeted treatment for non-small cell lung cancer (NSCLC), for example, NGS can detect alterations in genes such as EGFR, ALK, and ROS1 [14]. Finding driver mutations—the genetic changes that propel tumorigenesis—is one of the most significant uses of NGS in cancer research. Targeted medicines frequently target driver mutations. For instance, inhibitors like as vemurafenib can target mutations in the BRAF gene, which are frequently seen in melanoma [15, 16].

A new use of NGS is liquid biopsy, which analyzes blood samples to find tumor DNA (also known as circulating tumor DNA, or ctDNA). Early cancer identification, treatment response tracking, and low residual disease detection are all possible with this minimally invasive technique. NGS-assisted liquid biopsy has demonstrated promise in detecting genetic alterations in malignancies like prostate, colorectal, and breast cancer. The total number of mutations in a tumor's genome is known as the tumor mutational burden (TMB) [17]. Increased sensitivity to immune checkpoint inhibitors, a family of immunotherapies that aid the immune system in identifying and combating cancer cells, has been linked to elevated TMB. Clinicians can choose patients who might benefit from immunotherapy by using NGS to evaluate TMB. This is especially important for malignancies like NSCLC and melanoma. Additionally, NGS is essential for detecting genomic changes in uncommon tumors for whom there may be no proven treatment methods. For instance, NGS can assist in identifying particular gene rearrangements, fusions, or mutations that may present novel therapeutic options in uncommon sarcomas or hematologic malignancies [18].



Figure 1. Strategies and Targets in Cancer Gene Therapy

Targeted Therapies in Cancer Treatment: A New Era in Oncology

A class of cancer treatments known as "targeted therapies" focuses on the molecular changes present in cancer cells. Targeted therapies aim to disrupt specific chemicals or signalling pathways that support the growth and survival of cancer cells, in contrast to conventional chemotherapy, which affects both diseased and healthy cells. Targeted therapies offer the potential for more accurate and less harmful cancer treatment by focusing on these crucial biological mechanisms, thereby enhancing patient outcomes and quality of life [19].

Mechanisms of Targeted Therapies

Oncogenes are genes that encourage cell growth and survival, and their activation is the primary cause of many malignancies. Targeted therapies can specifically inhibit the activity of these oncogenes. The application of EGFR inhibitors to non-small cell lung cancer (NSCLC) is a good illustration. Uncontrolled cell division results from mutations in the EGFR gene, and medications such as gefitinib and erlotinib are used to disrupt the abnormal signaling pathway [20].

Enzymes called tyrosine kinases are part of the signaling cascades that control cell division, proliferation, and survival. Tyrosine kinase activity is dysregulated in several malignancies. These enzymes are the target of tyrosine kinase inhibitors (TKIs), like imatinib. For example, imatinib is used to prevent the BCR-ABL fusion protein, which is caused by the translocation of the Philadelphia chromosome, in chronic myelogenous leukemia (CML) [21].

Laboratory-produced molecules known as monoclonal antibodies (mAbs) are created to attach to certain sites on cancer cells, either inhibiting their function or designating them for immune system destruction. For instance, the HER2/neu receptor, which is overexpressed in some breast tumors, is the target of trastuzumab (Herceptin). Trastuzumab suppresses the development of cancer cells and promotes immune-mediated tumor elimination by attaching itself to the HER2 receptor [22].

Tumor growth and metastasis depend on angiogenesis, the process by which tumors create new blood vessels to carry nutrients and oxygen. One example of a targeted treatment is bevacizumab (Avastin), which stops the creation of new blood vessels inside tumors by attaching to and neutralizing vascular endothelial growth factor (VEGF). This prevents the tumor from growing and spreading [23].

A more recent line of targeted treatments called immune checkpoint inhibitors functions by inhibiting proteins that stifle the immune

system's reaction to malignancies. Cancer cells can avoid immune detection by inhibiting T-cell function using proteins like PD-1 and CTLA-4. Drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo) assist the immune system regain its capacity to recognize and eliminate cancer cells by blocking these checkpoints [24].

Monoclonal Antibodies (mAbs)

Laboratory-engineered molecules known as monoclonal antibodies (mAbs) are intended to target particular antigens present on the surface of cancer cells. They provide highly targeted treatment with few off-target effects, making them a key component of contemporary cancer therapy. mAbs are made to engage with specific proteins or receptors that promote the development and survival of cancer cells, in contrast to conventional chemotherapy, which indiscriminately targets both diseased and healthy cells. These treatments have the ability to directly stop the functions of cancer cells, identify them for immune system destruction, or stop the ways in which cancer cells avoid the immune system [25].

Mechanisms of Action

Antibody-dependent cellular cytotoxicity (ADCC) is a crucial mechanism via which monoclonal antibodies function. The monoclonal antibody attaches itself to particular antigens on the surface of tumor cells during this process. Immune cells like neutrophils, macrophages, and natural killer (NK) cells are drawn in by this binding. They identify the antibody-coated tumor cell and use cytotoxic processes to destroy it [26].

The complement system, a component of the immune system that aids antibodies in eliminating infections and cancer cells, can be activated by some monoclonal antibodies. The complement cascade may be triggered when an antibody binds to a tumor cell, encouraging the tumor cell to be lysed (destroyed) [27]. By preventing the activity of growth factors or receptors necessary for tumor cell proliferation, monoclonal antibodies can also stop the growth of tumors. For instance, trastuzumab (Herceptin) inhibits the growth of tumors by targeting the HER2 receptor, which is overexpressed in some breast cancer cells, and preventing its activation. Nivolumab and pembrolizumab are two examples of monoclonal antibodies that function by blocking immune checkpoint proteins like PD-1 or PD-L1 [28]. Cancer cells take advantage of these checkpoints to evade immune surveillance, even though they ordinarily stop the immune system from attacking healthy tissues. mAbs help T-cells identify and combat cancer cells more efficiently by inhibiting these proteins [29, 30].

Immune Checkpoint Inhibitors (ICIs)

A class of immunotherapeutic drugs known as immune checkpoint inhibitors (ICIs) has completely changed the way that many types of cancer are treated. These inhibitors function by preventing cancer cells from using immune checkpoint pathways to avoid immune surveillance. Programmed Cell Death Protein 1 (PD-1), Programmed Cell Death Ligand 1 (PD-L1), and Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) are the main immunological checkpoint proteins that ICIs target. ICIs improve the immune system's capacity to identify and eliminate cancer cells by obstructing these pathways [31].

Pembrolizumab and nivolumab, two PD-1 and PD-L1 inhibitors, are frequently used to treat melanoma, non-small cell lung cancer (NSCLC), and other malignancies. These substances stop T cells' PD-1 from attaching to tumor cells' PD-L1, which would otherwise result in immunological tolerance and tumor immune escape. However, CTLA-4 inhibitors, such as ipilimumab (Yervoy), work by preventing CTLA-4 from activating T cells, which prevents the immune system from responding to malignancies [32].

Although ICIs have demonstrated exceptional effectiveness in treating a range of

malignancies, there are several drawbacks to using them. Immunorelated adverse events (irAEs), which happen when the heightened immune response attacks healthy tissues, can happen to some patients. From minor symptoms like rash or diarrhea to serious issues affecting organs including the liver, lungs, and intestines, these side effects can vary widely. Tumor type, genetic alterations, and the tumor microenvironment are some of the other variables that affect the safety and effectiveness of immune checkpoint inhibitors. Although their predictive value is still being studied, biomarkers such as tumor mutational burden (TMB) and PD-L1 expression levels are frequently employed to forecast the possibility of a favorable response to treatment [33, 34].

Recent studies have concentrated on using combination therapy to increase the efficacy of ICIs. The anti-tumor immune response can be strengthened by combining PD-1/PD-L1 inhibitors with other immune-modulating drugs or traditional therapies like radiation and chemotherapy. In cancer immunotherapy, immune checkpoint inhibitors have, all things considered, been a major breakthrough, providing patients with formerly incurable tumors with new therapeutic alternatives. To minimize the related side effects, maximize their use, and comprehend their methods of action, more study is necessary [35, 36].

Combination Therapies

The employment of two or more therapeutic treatments either simultaneously or sequentially to improve therapeutic efficacy, get past resistance mechanisms, and lower the risk of relapse is known as combination therapy in the context of cancer treatment. When it comes to cancer immunotherapy, combination therapies usually entail combining immune checkpoint inhibitors (ICIs) with oncolytic viruses, chemotherapy, radiation therapy, targeted therapies, or other immunotherapeutic agents. Combination therapies aim to improve treatment results over monotherapy by boosting the immune response against malignancies and overcoming immune suppression in the tumor microenvironment [37].

Combination of Immune Checkpoint Inhibitors (ICIs)

Combining various ICIs is one of the most promising approaches. Anti-PD-1/PD-L1 and anti-CTLA-4 inhibitors, for example, have shown considerable clinical benefit when combined, particularly in melanoma and non-small cell lung cancer (NSCLC). It has been demonstrated that nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) work in concert, with PD-1 inhibition preventing the depletion of these activated T cells in the tumor microenvironment and CTLA-4 inhibition increasing T cell activation and priming [38].

Combination with Chemotherapy

One common treatment method that can directly destroy cancer cells is chemotherapy. By causing immunogenic cell death (ICD), which releases tumor antigens and improves antigen presentation, chemotherapy can boost immune responses when used in conjunction with immune checkpoint inhibitors. The combination of PD-1/PD-L1 inhibitors plus chemotherapy has been studied in a number of clinical studies, with encouraging outcomes in diseases like gastric cancer, triple-negative breast cancer (TNBC), and non-small cell lung cancer (NSCLC). Chemotherapy is justified by the fact that it can enhance immune cell penetration into tumors and foster a supportive immunological milieu [39].

Combination with Targeted Therapies

Tyrosine kinase inhibitors (TKIs) and other targeted medicines have completely changed the way that tumors with certain genetic changes—like EGFR mutations in non-small cell lung cancer—are treated. ICIs and targeted medicines together may have stronger anti-tumor effects. In order to overcome resistance mechanisms in NSCLC and other malignancies, for instance, the combination of

EGFR inhibitors with immune checkpoint inhibitors has showed promise. By modifying the tumor microenvironment, enhancing antigen presentation, and regulating immune cell infiltration, targeted therapies can make cancers more susceptible to immune-mediated death [40].

Combination with Radiation Therapy

Tyrosine kinase inhibitors (TKIs) and other targeted medicines have completely changed the way that tumors with certain genetic changes—like EGFR mutations in non-small cell lung cancer—are treated. ICIs and targeted medicines together may have stronger anti-tumor effects. In order to overcome resistance mechanisms in NSCLC and other malignancies, for instance, the combination of EGFR inhibitors with immune checkpoint inhibitors has showed promise. By modifying the tumor microenvironment, enhancing antigen presentation, and regulating immune cell infiltration, targeted therapies can make cancers more susceptible to immune-mediated death [41].

Combination with Oncolytic Viruses

Viruses used in oncolytic virotherapy specifically target and destroy cancer cells. Immunocheckpoint inhibitors and oncolytic viruses may work in concert to improve the immune system's capacity to recognize and eliminate malignancies. Through the promotion of immune cell infiltration and antigen presentation, oncolytic viruses have the ability to create a pro-inflammatory tumor microenvironment, which could enhance the effects of ICIs [42].

Biomarkers in Cancer Therapy

Blood, tissue, and other body fluids contain biological chemicals called biomarkers that can either predict how a patient will react to a certain treatment or show whether cancer is present. Biomarkers are essential tools for cancer therapy diagnosis, prognosis, and treatment selection, allowing for a more individualized approach to cancer care. Their capacity to direct the choice of treatments based on the molecular features of a patient's cancer has transformed the treatment of numerous cancers. Biomarkers can identify people at risk of negative treatment effects, track the course of a disease, and predict therapy response [43].

Role of Biomarkers in Cancer Treatment

The advancement of precision or tailored medicine is one of the most significant uses of biomarkers. Biomarkers provide treatment choices that are specific to each patient's tumor by examining the molecular features of the malignancy. For instance, in cases of breast cancer, HER2 expression and the status of the estrogen receptor (ER) and progesterone receptor (PR) dictate whether a patient should get hormone therapy or HER2-targeted treatment such as trastuzumab. To select the best targeted treatments for lung cancer, genetic testing for mutations in genes like EGFR, ALK, or ROS1 is crucial [44].

The application of immunotherapies and targeted medicines has been transformed by biomarkers. Testing for EGFR, ALK, or ROS1 mutations in non-small cell lung cancer (NSCLC) can aid in the patient selection process for targeted treatments like ALK or EGFR inhibitors. Similarly, only patients whose tumors express the PD-L1 protein can benefit from immune checkpoint inhibitors like as pembrolizumab and nivolumab. Tumor mutational burden (TMB) and microsatellite instability (MSI) are two biomarkers that can be used to predict how malignancies including melanoma, colorectal cancer, and non-small cell lung cancer would react to immune checkpoint inhibitors [45].

Biomarkers play a crucial role in tracking a patient's response to therapy. When it comes to identifying changes in tumor size, conventional techniques like imaging can be slow and occasionally unreliable. On the other hand, liquid biopsy methods that identify exosomes or circulating tumor DNA (ctDNA) provide a non-

invasive means of evaluating the efficacy of the treatment in real time. A good response may be indicated by a drop in ctDNA levels, whereas resistance or illness progression may be suggested by an increase [46, 47].

Additionally, biomarkers are essential for early relapse detection. Monitoring for the BCR-ABL fusion gene following treatment, for instance, can reveal early warning indicators of disease return in chronic myelogenous leukemia (CML) before clinical symptoms manifest. In a similar vein, ctDNA can be used to identify relapse in a number of malignancies, including lung and breast cancer, even in cases when imaging tests come back negative [48].



Figure 2. Biomarkers in Cancer Management

Challenges and Limitations in Precision Medicine

The genetic complexity and heterogeneity of tumors is one of the main obstacles in precision medicine, especially when it comes to treating cancer. Cancer cells are not homogeneous; they can differ significantly in their genetic makeup both within and across metastatic locations and within the same tumor. Because of this variety, it may be challenging to find a single biomarker that reliably informs therapy choices. The development of novel mutations that were absent at the time of diagnosis may cause a tumor to become resistant to a specific treatment after first responding to it. For instance, in non-small cell lung cancer (NSCLC), EGFR mutations may react at first to EGFR inhibitors; nevertheless, therapy failure may result from the emergence of resistance due to subsequent mutations such as T790M [49].

The restricted accessibility and availability of genetic testing, especially in low-resource environments, is a major drawback of precision medicine. Next-generation sequencing (NGS) and other comprehensive genomic tests can be costly and call for certain infrastructure and knowledge. Lack of access to these cutting-edge diagnostic resources may cause delays in diagnosis, which would reduce the possibility of early intervention and individualized treatment regimens. Furthermore, different nations have varying levels of access to genetic testing, which results in unfair healthcare delivery [50].

One of the biggest obstacles in precision medicine is still interpreting genomic data. Clinicians frequently find it difficult to interpret the growing volume of genomic data produced by high-throughput sequencing methods. It can be challenging to differentiate between benign variants and dangerous mutations, and not all genetic mutations or modifications are

clinically meaningful. Furthermore, to make precise treatment options, genetic data must be combined with additional elements like patient history, environmental exposures, and the tumor microenvironment. In many instances, it is still uncertain if genetic mutations or variants of unknown significance have any clinical consequence [51].

Another significant drawback of precision medicine is its high expense. Even though sequencing has become much less expensive in the last ten years, many patients still cannot afford tailored treatments and extensive genetic testing, particularly those without sufficient insurance. Precision medicine frequently uses biologic drugs and targeted medicines, which can be substantially more costly than traditional treatments. Many people's access to these treatments is restricted by this economic burden, especially in low- and middle-income nations [52].

There are several ethical and privacy issues with precision medicine's use of genomic data. Because genetic data is so sensitive, there is rising worry about its potential for misuse, including discrimination based on genetic predispositions. Another concern is inadvertent results, which occur when genetic testing reveals unanticipated information that may affect a patient's or their family members' health, such as an elevated risk for a genetic condition. In a clinical setting, it may be challenging to evaluate and handle these results. Strict privacy laws must also be followed while exchanging and storing genetic data in order to preserve patient anonymity [53. 54].

Future Directions in Precision Medicine and Cancer Therapy

By permitting treatments that are customized to the genetic and molecular features of specific tumors, precision medicine has completely changed the field of cancer therapy. Even if tailored medicines and diagnostic tools have advanced significantly, even more improvements in cancer therapy are anticipated in the future. The future generation of precision oncology is probably going to be shaped by a number of new technologies, therapeutic approaches, and molecular discoveries. However, in order to assure their widespread and successful application, these improvements present certain obstacles that must be addressed [55].

It is anticipated that multi-omics techniques, including as genomes, transcriptomics, proteomics, and metabolomics, would be increasingly integrated into precision medicine in the treatment of cancer in the future. A more thorough understanding of cancer is made possible by the distinct aspects of tumor biology that each of these "omics" layers offers. The intricacy of tumor heterogeneity may be beyond the scope of genomic data alone, but by merging information from multiple omics platforms, physicians can better understand how cancer develops and how treatments work [56].

There is great potential for the future of cancer diagnosis and therapy monitoring using liquid biopsy, a non-invasive method for finding genetic changes and biomarkers in blood or other body fluids. With liquid biopsy, circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other tumor-derived components can be found, giving a glimpse into the tumor's genetic makeup. This method enables early relapse identification, minimal residual disease (MRD) diagnosis, and real-time monitoring of therapy responses [57].

Liquid biopsy technologies will probably become a commonplace instrument in clinical oncology as they develop further. Their capacity to offer continuous and less intrusive sampling has the potential to completely transform the way cancer is tracked and managed by enabling more frequent therapy modifications based on real-time genetic data. Additionally, unusual mutations or genetic changes that could cause tumor resistance to

existing treatments could be found using liquid biopsies [58].

Patients with melanoma, lung cancer, and other cancers have benefited greatly from immunotherapy, which has transformed the treatment of cancer. This is especially true with immune checkpoint inhibitors such as PD-1/PD-L1 and CTLA-4 inhibitors. However, resistance mechanisms can emerge over time, and not all patients respond to immunotherapy [59]. In order to overcome resistance and improve therapeutic efficacy, immune checkpoint inhibitors will probably be used in combination strategies with targeted treatments, chemotherapy, or radiation in the future of cancer immunotherapy [60].

Precision medicine and cancer treatment seem to benefit greatly from the application of artificial intelligence (AI) and machine learning (ML) [61]. Large volumes of complicated data, including as genomic sequences, imaging, and clinical records, can be analyzed by these technologies to find patterns that are difficult for human clinicians to notice. Algorithms using AI and ML could enhance early detection, forecast patient reactions to therapy, and enhance therapeutic approaches [62-65].

Conclusion

Advances in multi-omics integration, liquid biopsy technologies, immunotherapy, artificial intelligence, and gene editing methods like CRISPR hold great promise for the future of precision medicine and cancer treatment. These developments have the potential to improve cancer therapy personalization by providing more precise and efficient treatments with fewer adverse effects. To guarantee that the advantages of precision medicine are available to everyone, however, issues like the intricacy of cancer genomics, exorbitant expenses, restricted access in low-resource environments, and the requirement for strong clinical evidence must be resolved. To fully fulfill precision oncology's promise and enhance cancer care worldwide, more research, teamwork, and initiatives toward healthcare equity are required.

Reference

[1]. Collins, F. S., and Varmus, H., 2015, A new initiative on precision medicine, *New England Journal of Medicine*, 372(9), 793-795.

[2]. National Research Council, 2011, Toward precision medicine: Building a knowledge network for biomedical research and a new taxonomy of disease, *National Academies Press*.

[3]. Ashley, E. A., 2015, The precision medicine initiative: a new national effort, *JAMA*, 313(21), 2119-2120.

[4]. Szalai, R., Hadzsiev, K., and Melegh, B., 2016, Cytochrome P450 drug metabolizing enzymes in Roma population samples: systematic review of the literature, *Current Medicinal Chemistry*, 23(31), 3632-3652.

[5]. Advani, D., Sharma, S., Kumari, S., Ambasta, R. K., and Kumar, P., 2022, Precision oncology, signaling, and anticancer agents in cancer therapeutics, *Anti-Cancer Agents in Medicinal Chemistry*, 22(3), 433-468.

[6]. Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., and Brown, P. O., 2000, Systematic variation in gene expression patterns in human cancer cell lines, *Nature Genetics*, 24(3), 227-235.

[7]. Bashor, C. J., Hilton, I. B., Bandukwala, H., Smith, D. M., and Veiseh, O., 2022, Engineering the next generation of cell-based therapeutics, *Nature Reviews Drug Discovery*, 21(9), 655-675.

[8]. Stratton, M. R., Campbell, P. J., and Futreal, P. A., 2009, The cancer genome, *Nature*, 458(7239), 719-724.

[9]. Hurley, J., Doliny, P., Reis, I., Silva, O., Gomez-Fernandez, C., Velez, P., and Slamon, D. J., 2006, Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2–positive locally advanced breast cancer, *Journal of Clinical Oncology*, 24(12), 1831-1838.

[10]. Abdel-Aziz, A. K., Abdel-Naim, A. B., Shouman, S., Minucci, S., and Elgendy, M., 2017, From resistance to sensitivity: insights and implications of biphasic modulation of autophagy by sunitinib, *Frontiers in Pharmacology*, 8, 718.

[11]. Zhang, L. J., Gan, Y. M., and Yu, L., 2015, Occurrence of BCR/ABL fusion gene in a patient with acute promyelocytic leukemia, *Medical Oncology*, 32, 1-3.

[12]. Mardis, E. R., 2008, Next-generation DNA sequencing methods, *Annual Review of Genomics and Human Genetics*, 9(1), 387-402.

[13]. Sabour, L., Sabour, M., and Ghorbian, S., 2017, Clinical applications of next-generation sequencing in cancer diagnosis, *Pathology & Oncology Research*, 23, 225-234.

[14]. Kyrochristos, I. D., Glantzounis, G. K., Ziogas, D. E., Gizas, I., Schizas, D., Lykoudis, E. G., and Roukos, D. H., 2017, From clinical standards to translating next-generation sequencing research into patient care improvement for hepatobiliary and pancreatic cancers, *International Journal of Molecular Sciences*, 18(1), 180.

[15]. Lazaro, T., and Brastianos, P. K., 2017, Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine, *CNS Oncology*, 6(2), 139-151.

[16]. Ferreira-Gonzalez, A., Ko, G., Fusco, N., Stewart, F., Kistler, K., Appukkuttan, S., and Babajanyan, S., 2024, Barriers and facilitators to next-generation sequencing use in United States oncology settings: a systematic review, *Future Oncology*, 20(35), 2765-2777.

[17]. Chen, M., and Zhao, H., 2019, Next-generation sequencing in liquid biopsy: cancer screening and early detection, *Human Genomics*, 13(1), 34.

[18]. Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., and Frampton, G. M., 2017, Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden, *Genome Medicine*, 9, 1-14.

[19]. Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., and Larson, R. A., 2006, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia, *New England Journal of Medicine*, 355(23), 2408-2417.

[20]. Nahta, R., 2012, Molecular mechanisms of trastuzumab-based treatment in HER2-overexpressing breast cancer, *International Scholarly Research Notices*, 2012(1), 428062.

[21]. Shaw, A. T., Ou, S. H. I., Bang, Y. J., Camidge, D. R., Solomon, B. J., Salgia, R., and Iafrate, A. J., 2014, Crizotinib in ROS1-rearranged non–small-cell lung cancer, *New England Journal of Medicine*, 371(21), 1963-1971.

[22]. Krzyszczyk, P., Acevedo, A., Davidoff, E. J., Timmins, L. M., Marrero-Berrios, I., Patel, M., and Yarmush, M. L., 2018, The growing role of precision and personalized medicine for cancer treatment, *Technology*, 6(03n04), 79-100.

[23]. Hauschild, A., Grob, J. J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., and Chapman, P. B., 2012, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, *The Lancet*, 380(9839), 358-365.

[24]. Saltz, L. B., Lenz, H. J., Kindler, H. L., Hochster, H. S., Wadler, S., Hoff, P. M., and Chen, H. X., 2007, Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study, *Journal of Clinical Oncology*, 25(29), 4557-4561.

[25]. Malani, P. N., 2012, Harrison's principles of internal medicine, *JAMA*, 308(17), 1813-1814.

[26]. Ribas, A., and Wolchok, J. D., 2018, Cancer immunotherapy using checkpoint blockade, *Science*, 359(6382), 1350-1355.

[27]. Zhang, Q., Huo, G. W., Zhang, H. Z., and Song, Y., 2020, Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis, *Open Medicine*, 15(1), 447-456.

[28]. Si, Y., Melkonian, A. L., Curry, K. C., Xu, Y., Tidwell, M., Liu, M., and Liu, X. M., 2021, Monoclonal antibody-based cancer therapies, *Chinese Journal of Chemical Engineering*, 30, 301-307.

[29]. Ayodele, O., and Razak, A. A., 2020, Immunotherapy in soft-tissue sarcoma, *Current Oncology*, 27(Suppl 1), 17.

[30]. Kimiz-Gebologlu, I., Gulce-Iz, S., and Biray-Avci, C., 2018, Monoclonal antibodies in cancer immunotherapy, *Molecular Biology Reports*, 45(6), 2935-2940.

[31]. Malani, P. N., 2012, Harrison's principles of internal medicine, *JAMA*, 308(17), 1813-1814.

[32]. Ribas, A., and Wolchok, J. D., 2018, Cancer immunotherapy using checkpoint blockade, *Science*, 359(6382), 1350-1355.

[33]. Zhang, Q., Huo, G. W., Zhang, H. Z., and Song, Y., 2020, Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis, *Open Medicine*, 15(1), 447-456.

[34]. Si, Y., Melkonian, A. L., Curry, K. C., Xu, Y., Tidwell, M., Liu, M., and Liu, X. M., 2021, Monoclonal antibody-based cancer therapies, *Chinese Journal of Chemical Engineering*, 30, 301-307.

[35]. In, G. K., Hu, J. S., and Tseng, W. W., 2017, Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations, *Therapeutic Advances in Medical Oncology*, 9(8), 533-550.

[36]. Kimiz-Gebologlu, I., Gulce-Iz, S., and Biray-Avci, C., 2018, Monoclonal antibodies in cancer immunotherapy, *Molecular Biology Reports*, 45(6), 2935-2940.

[37]. Janne, P. A., Engelman, J. A., and Johnson, B. E., 2005, Epidermal growth factor receptor mutations in non–small-cell lung cancer: implications for treatment and tumor biology, *Journal of Clinical Oncology*, 23(14), 3227-3234.

[38]. Hudis, C. A., and Gianni, L., 2011, Triple-negative breast cancer: an unmet medical need, *The Oncologist*, 16(S1), 1-11.

[39]. Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., and Sorensen, A. G., 2009, Biomarkers of response and resistance to antiangiogenic therapy, *Nature Reviews Clinical Oncology*, 6(6), 327-338.

[40]. Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., and Diaz Jr, L. A., 2015, PD-1 blockade in tumors with mismatch-repair deficiency, *New England Journal of Medicine*, 372(26), 2509-2520.

[41]. McGranahan, N., and Swanton, C., 2015, Biological and therapeutic impact of intratumor heterogeneity in cancer evolution, *Cancer Cell*, 27(1), 15-26.

[42]. Grigg, C., and Rizvi, N. A., 2016, PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?, *Journal for Immunotherapy of Cancer*, 4(1), 48.

[43]. Lim, S. M., Syn, N. L., Cho, B. C., and Soo, R. A., 2018, Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: mechanisms and therapeutic strategies, *Cancer Treatment Reviews*, 65, 1-10.

[44]. McCarthy, J. J., McLeod, H. L., and Ginsburg, G. S., 2013, Genomic medicine: a decade of successes, challenges, and opportunities, *Science Translational Medicine*, 5(189), 189sr4-189sr4.

[45]. Choi, H. Y., and Chang, J. E., 2023, Targeted therapy for cancers: from ongoing clinical trials to FDA-approved drugs, *International Journal of Molecular Sciences*, 24(17), 13618.

[46]. Tesi, B., Boileau, C., Boycott, K. M., Canaud, G., Caulfield, M., Choukair, D., and Lindstrand, A., 2023, Precision medicine in rare diseases: what is next?, *Journal of Internal Medicine*, 294(4), 397-412.

[47]. Sharma, S. V., Bell, D. W., Settleman, J., and Haber, D. A., 2007, Epidermal growth factor receptor mutations in lung cancer, *Nature Reviews Cancer*, 7(3), 169-181.

[48]. Islam, A., Shaukat, Z., Hussain, R., and Gregory, S. L., 2022, One-carbon and polyamine metabolism as cancer therapy targets, *Biomolecules*, 12(12), 1902.

[49]. Zhang, Z., Stiegler, A. L., Boggon, T. J., Kobayashi, S., and Halmos, B., 2010, EGFR-mutated lung cancer: a paradigm of molecular oncology, Oncotarget, 1(7), 497.

[50]. Mosele, F., Remon, J., Mateo, J., Westphalen, C. B., Barlesi, F., Lolkema, M. P., and André, F., 2020, Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO

Precision Medicine Working Group, *Annals of Oncology*, 31(11), 1491-1505.

[51]. Wu, J., and Lin, Z., 2022, Non-small cell lung cancer targeted therapy: drugs and mechanisms of drug resistance, *International Journal of Molecular Sciences*, 23(23), 15056.

[52]. Bahar, M. E., Kim, H. J., and Kim, D. R., 2023, Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies, *Signal Transduction and Targeted Therapy*, 8(1), 455.

[53]. Ke, X., and Shen, L., 2017, Molecular targeted therapy of cancer: The progress and future prospect, *Frontiers in Laboratory Medicine*, 1(2), 69-75.

[54]. Bai, R., Chen, N., Li, L., Du, N., Bai, L., Lv, Z., and Cui, J., 2020, Mechanisms of cancer resistance to immunotherapy, *Frontiers in Oncology*, 10, 1290.

[55]. Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., and Diaz Jr, L. A., 2015, PD-1 blockade in tumors with mismatch-repair deficiency, *New England Journal of Medicine*, 372(26), 2509-2520.

[56]. McGranahan, N., and Swanton, C., 2015, Biological and therapeutic impact of intratumor heterogeneity in cancer evolution, *Cancer Cell*, 27(1), 15-26.

[57]. Breimer, L. H., Nousios, P., Olsson, L., and Brunnström, H., 2020, Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm, *Scandinavian Journal of Clinical and Laboratory Investigation*, 80(5), 360-369.

[58]. Lim, S. M., Syn, N. L., Cho, B. C., and Soo, R. A., 2018, Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: mechanisms and therapeutic strategies, *Cancer Treatment Reviews*, 65, 1-10.

[59]. McCarthy, J. J., McLeod, H. L., and Ginsburg, G. S., 2013, Genomic medicine: a decade of successes, challenges, and opportunities, *Science Translational Medicine*, 5(189), 189sr4-189sr4.

[60]. Cervello, M., McCubrey, J. A., Cusimano, A., Lampiasi, N., Azzolina, A., and Montalto, G., 2012, Targeted therapy for hepatocellular carcinoma: novel agents on the horizon, *Oncotarget*, 3(3), 236.

[61]. Mosele, F., Remon, J., Mateo, J., Westphalen, C. B., Barlesi, F., Lolkema, M. P., and André, F., 2020, Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group, *Annals of Oncology*, 31(11), 1491-1505.

[62]. Banerjee, D., Bhattacharya, A., Puri, A., Munde, S., Mukerjee, N., Mohite, P., and Al Shmrany, H., 2024, Innovative approaches in stem cell therapy: revolutionizing cancer treatment and advancing neurobiology–a comprehensive review, *International Journal of Surgery*, 110(12), 445-461.

[63]. Shanmugarathinam, A., Elamaran, N., Kirubakaran, D., Irulappan, G.B., Baig, A.A. and Vasantharaj, K., 2025, Sustainable Synthesis of Zinc Oxide Nanoparticles from Vicoa indica Leaf Extract: Characterization and Evaluation of Antibacterial, Antioxidant, and Anticancer Properties. *Biomedical Materials & Devices*, 1-16.

[64]. Malakondaiah, S., Pavithravedhavalli, V., Kayal, L., Ryntathiang, I., and Jothinathan, M. K. D., 2024, Stem cell therapy: A new path in tackling oral cancer. *Journal of Stomatology, Oral and Maxillofacial Surgery*, 101967.

[65]. Shekar, N. D., Kayal, L., Babu, N. A., Jothinathan, M. K. D., and Ryntathiang, I., 2024, Pioneering the use of micro-biomarkers in oral cancer detection. *Oral Oncology Reports*, 100412.